Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vandana S Mathur

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The American Journal of Cardiology|March 28, 2006
Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterizationPaul S Teirstein, Matthew J Price, Vandana S Mathur, et al.
International Journal of Nephrology and Renovascular Disease|February 9, 2017
Chronic kidney disease-associated pruritus: impact on quality of life and current management challengesShayan Shirazian, Olufemi Aina, Youngjun Park, et al.
Journal of Cardiac Failure|August 7, 2007
High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE databaseJ Thomas Heywood, Gregg C Fonarow, Maria Rosa Costanzo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 19, 2010
A longitudinal study of uremic pruritus in hemodialysis patientsVandana S Mathur, Jill Lindberg, Michael Germain, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|June 3, 2008
Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trialBrian R Leaker, B O'Connor, Trevor T Hansel, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|January 20, 2009
The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imagingGregory S Thomas, Randall C Thompson, Michael I Miyamoto, et al.
Blood Advances|February 25, 2020
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteersGenmin Lu, Pamela B Conley, Janet M Leeds, et al.
Journal of the American Society of Nephrology : JASN|December 4, 2020
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialPablo E Pergola, Matt Devalaraja, Steven Fishbane, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 4, 2022
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosisVandana S Mathur, David A Bushinsky, Lesley Inker, et al.
Journal of the American Society of Nephrology : JASN|January 23, 2024
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic AcidosisNavdeep Tangri, Vandana S Mathur, David A Bushinsky, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The American Journal of Cardiology|March 28, 2006
Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterizationPaul S Teirstein, Matthew J Price, Vandana S Mathur, et al.
International Journal of Nephrology and Renovascular Disease|February 9, 2017
Chronic kidney disease-associated pruritus: impact on quality of life and current management challengesShayan Shirazian, Olufemi Aina, Youngjun Park, et al.
Journal of Cardiac Failure|August 7, 2007
High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE databaseJ Thomas Heywood, Gregg C Fonarow, Maria Rosa Costanzo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 19, 2010
A longitudinal study of uremic pruritus in hemodialysis patientsVandana S Mathur, Jill Lindberg, Michael Germain, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|June 3, 2008
Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trialBrian R Leaker, B O'Connor, Trevor T Hansel, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|January 20, 2009
The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imagingGregory S Thomas, Randall C Thompson, Michael I Miyamoto, et al.
Blood Advances|February 25, 2020
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteersGenmin Lu, Pamela B Conley, Janet M Leeds, et al.
Journal of the American Society of Nephrology : JASN|December 4, 2020
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialPablo E Pergola, Matt Devalaraja, Steven Fishbane, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 4, 2022
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosisVandana S Mathur, David A Bushinsky, Lesley Inker, et al.
Journal of the American Society of Nephrology : JASN|January 23, 2024
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic AcidosisNavdeep Tangri, Vandana S Mathur, David A Bushinsky, et al.
Pageof 3